Exact Sciences price target lowered to $60 from $65 at BTIG

BTIG analyst Mark Massaro lowered the firm’s price target on Exact Sciences (EXAS) to $60 from $65 and keeps a Buy rating on the shares. The firm’s management team meetings after the “surprising” Freenome deal has left it more positive for the outlook of both companies, the analyst tells investors in a research note. Exact Sciences has pivoted very quickly from its setback in its own blood program and de-risked to some extent the threat of blood-based competition from Guardant Health (GH), the firm added.